Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myelodysplasias

Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies

Leukemia volume 22, pages 544–550 (2008)Cite this article

Abstract

The differences in clinical features and prognosis between hypoplastic myelodysplastic syndrome (h-MDS) and normo-/hypercellular MDS (NH-MDS) remain unsettled. In this study, the characteristics of 37 h-MDS patients and 152 NH-MDS patients were compared. Peripheral-blood white blood cell counts and bone marrow blast percentage were lower in h-MDS patients than in NH-MDS patients (P=0.012 and 0.016, respectively). Refractory anemia (RA) was predominant (56.8%) in h-MDS, whereas RA with excess of blast (RAEB) was most common (44.7%) in NH-MDS. Chromosomal abnormalities −7/7q− occurred less frequently in h-MDS patients than in NH-MDS patients (0 vs 18.3%, P=0.022). There was no significant difference in the prevalence of mutations of RAS, AML1, JAK2, PTPN11, FLT3/ITD, and hypermethylation of SOCS1 and SHP1 between these two groups. International Prognostic Scoring System (IPSS) was ideal for predicting prognoses in h-MDS patients (P=0.002). In low- or intermediate-1 (Int-1)-risk MDS patients, h-MDS patients had a superior survival than NH-MDS patients (P=0.01). In conclusion, distinct from NH-MDS, h-MDS patients have different patterns of hemogram, distribution of French–American–British subtypes, cytogenetic changes and prognoses. IPSS is applicable in h-MDS as in NH-MDS. In patients with low- or Int-1-risk MDS, h-MDS patients have a better prognosis than NH-MDS patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Barrett J, Saunthararajah Y, Molldrem J . Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37: 15–29.

    Article  CAS  Google Scholar 

  2. Nand S, Godwin JE . Hypoplastic myelodysplastic syndrome. Cancer 1988; 62: 958–964.

    Article  CAS  Google Scholar 

  3. Chen B, Zhao WL, Jin J, Xue YQ, Cheng X, Chen XT et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005; 19: 767–775.

    Article  CAS  Google Scholar 

  4. Lee JH, Lee JH, Shin YR, Lee JS, Kim WK, Chi HS et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003; 17: 305–313.

    Article  Google Scholar 

  5. Greenberg PL . Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998; 22: 1123–1136.

    Article  CAS  Google Scholar 

  6. Tien HF, Tang JH, Tsay W, Liu MC, Lee FY, Wang CH et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001; 112: 148–154.

    Article  CAS  Google Scholar 

  7. Wu SJ, Yao M, Chou WC, Tang JL, Chen CY, Ko BS et al. Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol 2006; 135: 317–323.

    Article  CAS  Google Scholar 

  8. Backx B, Broeders L, Touw I, Lowenberg B . Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia 1993; 7: 75–79.

    CAS  Google Scholar 

  9. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP . Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001; 29: 1270–1277.

    Article  CAS  Google Scholar 

  10. Nakao M, Horiike S, Fukushima-Nakase Y, Nishimura M, Fujita Y, Taniwaki M et al. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. Br J Haematol 2004; 125: 709–719.

    Article  CAS  Google Scholar 

  11. Georgiou G, Karali V, Zouvelou C, Kyriakou E, Dimou M, Chrisochoou S et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br J Haematol 2006; 134: 302–306.

    Article  CAS  Google Scholar 

  12. Paquette RL, Landaw EM, Pierre RV, Kahan J, Lubbert M, Lazcano O et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82: 590–599.

    CAS  Google Scholar 

  13. Tien HF, Wang CH, Chuang SM, Chow JM, Lee FY, Liu MC et al. Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome. A study on 68 Chinese patients in Taiwan. Cancer Genet Cytogenet 1994; 74: 40–49.

    Article  CAS  Google Scholar 

  14. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  Google Scholar 

  15. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.

    Article  CAS  Google Scholar 

  16. Tien HF, Wang CH, Chen YC, Shen MC, Lin DT, Lin KH . Characterization of acute myeloid leukemia (AML) coexpressing lymphoid markers: different biologic features between T-cell antigen positive and B-cell antigen positive AML. Leukemia 1993; 7: 688–695.

    CAS  Google Scholar 

  17. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, Werner M, Choritz H, Mainzer K et al. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol 1993; 66: 117–122.

    Article  CAS  Google Scholar 

  18. Tuzuner N, Cox C, Rowe JM, Bennett JM . Bone marrow cellularity in myeloid stem cell disorders: impact of age correction. Leuk Res 1994; 18: 559–564.

    Article  CAS  Google Scholar 

  19. Brodsky RA, Jones RJ . Aplastic anaemia. Lancet 2005; 365: 1647–1656.

    Article  CAS  Google Scholar 

  20. Chou WC, Tang JL, Lin LI, Yao M, Tsay W, Chen CY et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006; 66: 3310–3316.

    Article  CAS  Google Scholar 

  21. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T . High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004; 103: 2316–2324.

    Article  CAS  Google Scholar 

  22. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005; 11: 1372–1379.

    Article  CAS  Google Scholar 

  23. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002; 100: 2387–2392.

    Article  CAS  Google Scholar 

  24. Chen CY, Lin LI, Tang JL, Tsay W, Chang HH, Yeh YC et al. Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia 2006; 20: 1155–1158.

    Article  Google Scholar 

  25. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005; 19: 1536–1542.

    Article  CAS  Google Scholar 

  26. Chen CY, Tsay W, Tang JL, Shen HL, Lin SW, Huang SY et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 2003; 37: 300–305.

    Article  CAS  Google Scholar 

  27. Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 2002; 62: 6390–6394.

    CAS  Google Scholar 

  28. Bartl R, Frisch B, Baumgart R . Morphologic classification of the myelodysplastic syndromes (MDS): combined utilization of bone marrow aspirates and trephine biopsies. Leuk Res 1992; 16: 15–33.

    Article  CAS  Google Scholar 

  29. Delacretaz F, Schmidt PM, Piguet D, Bachmann F, Costa J . Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol 1987; 87: 180–186.

    Article  CAS  Google Scholar 

  30. Kitagawa M, Kamiyama R, Takemura T, Kasuga T . Bone marrow analysis of the myelodysplastic syndromes: histological and immunohistochemical features related to the evolution of overt leukemia. Virchows Arch B Cell Pathol Incl Mol Pathol 1989; 57: 47–53.

    Article  CAS  Google Scholar 

  31. Lambertenghi-Deliliers G, Annaloro C, Oriani A, Soligo D, Pozzoli E, Polli EE . Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes. Ann Hematol 1993; 66: 85–91.

    Article  CAS  Google Scholar 

  32. Mangi MH, Mufti GJ . Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood 1992; 79: 198–205.

    CAS  Google Scholar 

  33. Rios A, Canizo MC, Sanz MA, Vallespi T, Sanz G, Torrabadella M et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol 1990; 75: 26–33.

    Article  CAS  Google Scholar 

  34. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H et al. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes. Int J Hematol 1993; 58: 53–61.

    CAS  Google Scholar 

  35. Tricot G, De Wolf-Peeters C, Hendrickx B, Verwilghen RL . Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol 1984; 57: 423–430.

    Article  CAS  Google Scholar 

  36. Yoshida Y, Oguma S, Uchino H, Maekawa T . Refractory myelodysplastic anaemias with hypocellular bone marrow. J Clin Pathol 1988; 41: 763–767.

    Article  CAS  Google Scholar 

  37. Jaffe ES . Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon. Oxford University Press: Oxford, 2001, pp 47.

    Google Scholar 

  38. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849.

    Article  CAS  Google Scholar 

  39. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM . Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Haematol 1995; 91: 612–617.

    Article  CAS  Google Scholar 

  40. Chen CY, Lin LI, Tang JL, Ko BS, Tsay W, Chou WC et al. RUNX1 gene mutation in primary myelodysplastic syndrome—the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007; 139: 405–414.

    Article  CAS  Google Scholar 

  41. Riccardi A, Giordano M, Girino M, Cazzola M, Montecucco CM, Cassano E et al. Refractory cytopenias: clinical course according to bone marrow cytology and cellularity. Blut 1987; 54: 153–163.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was sponsored in part by grants from the National Science Council of Taiwan NSC 94-2314-B-002-143 and 95-2314-B-002-042. We are grateful to Ms Fen-Yu Lee and Ms Min-Chih Liu for their help in chromosome study.

Author information

Author notes

  1. T-C Huang and J-L Tang: These authors contributed equally to this work.

Authors and Affiliations

  1. Division of Hemato-Oncology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

    T-C Huang, B-S Ko, J-L Tang, C Hsu, C-Y Chen, W Tsay, S-Y Huang, M Yao, Y-C Chen, M-C Shen, C-H Wang & H-F Tien

Authors
  1. T-C Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B-S Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J-L Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C-Y Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W Tsay
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S-Y Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y-C Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M-C Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C-H Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H-F Tien
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H-F Tien.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, TC., Ko, BS., Tang, JL. et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. Leukemia 22, 544–550 (2008). https://doi.org/10.1038/sj.leu.2405076

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2405076

Keywords

This article is cited by

Search

Advanced search

Quick links